JUL 01, 2020 8:00 AM PDT

Applied Biosystems™ TaqPath™ COVID-19 Combo Kit*: A highly sensitive, specific, and robust real-time PCR test

Sponsored by: Thermo Fisher Scientific

Event Date & Time

DATE:  July 1, 2020

TIME:   8:00 am PDT, 11:00 am EDT



In late 2019, researchers identified the SARS-CoV-2 pathogen as the virus responsible for COVID-19. The virus spread rapidly throughout the world and was declared a global health concern by the World Health Organization. At the end of January 2020, Thermo Fisher Scientific launched a SARS-CoV-2 pathogen detection assay, which was quickly developed into a multiplex kit containing highly specific assays and controls targeting three different regions of the SARS-CoV-2 genome. The kit was approved for Emergency Use Authorization (EUA) by the United States Food and Drug Administration in March, and has since been used as a central component of other EUA approved protocols.


Learning Objectives:

  • The development of Applied Biosystems™ TaqPath™ COVID-19 Combo Kit, including target selection
  • Performance data and the Thermo Fisher Scientific EUA protocol
  • Performance data from clinical laboratories using the TaqPath COVID-19 Combo Kit for the detection of RNA from SARS-CoV-2 under their own EUA protocols
  • A list of all approved EUA test kits and protocols can be found here


* For Emergency Use Authorization (EUA) only. For prescription use only. For in vitro diagnostic use.



*The content in this webinar pertains to the Applied Biosystems TaqPath COVID-19 Combo Kit which is registered for use in the United States of America, Australia, New Zealand, Canada, Israel, South Africa, India, Indonesia, Malaysia, The Philippines, Singapore and Taiwan.


Webinars will be available for unlimited on-demand viewing after live event.


LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.

You May Also Like
Loading Comments...